$GRCE News

Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference

Grace Therapeutics Files Prospectus For Offering 4.762M Common Shares On Behalf Of Selling Shareholders

Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update

Grace Therapeutics Q1 EPS $(0.91) Misses $(0.18) Estimate

Grace Therapeutics Announces $10 Million Private Placement

Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration

Grace Therapeutics Receives FDA Meeting Minutes From Type A Meeting; FDA Confirms No Clinical Safety Or Efficacy Deficiencies

Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update

Grace Therapeutics Q4 EPS $(0.06) Beats $(0.15) Estimate

Grace Therapeutics: Assessing The Path Forward For GTx-104

TD Cowen Maintains Buy on Grace Therapeutics, Lowers Price Target to $8

Grace Therapeutics Stock Falls As FDA Declines To Approve Brain Hemorrhage Drug

Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104

Grace Therapeutics Shares Resume Trade

Grace Therapeutics Shares Resume Trade

Grace Therapeutics Shares Resume Trade Then Halted On Circuit Breaker To The Downside, Stock Now Down -52.44%

Trading Halt: Halt status updated at 1:35:00 PM ET: Quotation Resumption: News and Resumption Times

Grace Therapeutics, Inc. Receives FDA Complete Response Letter For GTx-104, No New Clinical Data Required; Intends To Resubmit Application Following Resolution Of Cited Items

Trading Halt: Halted at 12:27:43 p.m. ET - Trading Halt: Halt News Pending

Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026